UCB and Microsoft team up to accelerate drug development

Pharmaceutical company UCB is expanding its partnership with Microsoft to accelerate drug discovery and development, especially for severe diseases in immunology and neurology. To this end, UCB’s scientists and data specialists will be able to rely on artificial intelligence (AI), advanced computing technology and data platforms. They want to discover new correlations and patterns that are crucial for finding highly individualised treatments and medicines that are tailored to the patient.